EDIT Stock Risk & Deep Value Analysis
Editas Medicine Inc
DVR Score
out of 10
What You Need to Know About EDIT Stock
We analyzed Editas Medicine Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran EDIT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
EDIT Risk Analysis & Red Flags
What Could Go Wrong
The company is burning significant cash with limited runway, necessitating further dilutive capital raises. If EDIT-301's clinical data is not exceptionally compelling, or if competitors solidify their leads, Editas could struggle to attract partners or secure meaningful market share, leading to substantial stock depreciation.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Persistent negative free cash flow with current short cash runway (<12 months)
- ⚠
High probability of further significant share dilution in the next 12-18 months
- ⚠
Lack of truly differentiated clinical data for lead asset against approved competitor therapies
- ⚠
Market capitalization has significantly eroded over the past year due to operational challenges
Upcoming Risk Events
- 📅
EDIT-301 clinical trial delays or unfavorable safety/efficacy data
- 📅
Dilutive financing event due to short cash runway
- 📅
Competitor advancements or approvals in target indications
When to Reconsider
- 🚪
Exit if EDIT-301 clinical data is underwhelming or shows significant safety issues
- 🚪
Sell if cash runway falls below 6 months without clear funding path or partnership
- 🚪
Exit if stock price breaks $1.50 support on heavy volume without specific negative news
Unlock EDIT Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Editas Medicine is a high-risk, high-reward speculative play on the potential for EDIT-301 to deliver unexpectedly superior clinical data in severe genetic diseases, despite being a 'fast follower.' Investment hinges on strategic partnerships leveraging its foundational CRISPR IP to secure a niche in a rapidly evolving, competitive landscape and avoid significant dilution.
Is EDIT Stock Undervalued?
Unlock the full AI analysis for EDIT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
EDIT Price Targets & Strategy
12-Month Target
$3.00
Bull Case
$5.50
Bear Case
$1.00
Valuation Basis
Based on a highly speculative 1.5x Price/Sales multiple on projected 2027 revenue ($2M, assuming early-stage partnership milestone revenue) if EDIT-301 Phase 1/2 data is positive.
Entry Strategy
Dollar-cost average between $1.75-$2.20 (testing recent lows and potential support if near-term news is positive). Caution advised due to high volatility.
Exit Strategy
Take 50% profit at $4.00; consider full exit above $5.50. Stop loss at $1.50 if cash burn accelerates without clinical progress.
Portfolio Allocation
1-3% for aggressive risk tolerance, highly speculative portion of portfolio.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does EDIT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
1 Identified
The foundational IP provides a narrow moat, but its durability is eroding rapidly due to aggressive competition, alternative gene editing technologies, and the necessity of clinical execution and commercialization to translate IP into market leadership. Without successful clinical data and partnerships, the IP's value diminishes.
Moat Erosion Risks
- •Challenges from competing CRISPR platforms (e.g., base editing, prime editing) and other gene therapy modalities
- •Patent expiration or successful challenges to core IP in key markets
- •Faster and more effective clinical development by rivals leading to market dominance
EDIT Competitive Moat Analysis
Sign up to see competitive advantages
EDIT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bearish. Some retail interest due to speculative CRISPR potential, but general sentiment is cautious due to competitive pressures and financial instability.
Institutional Sentiment
Neutral to Negative. Analysts largely hold cautious ratings (Hold/Underperform), with some target price reductions reflecting ongoing challenges. Institutional ownership has shown some exits.
Insider Activity (Form 4)
Normal activity observed, no significant Form 4 filings indicating material insider buying or selling in the past 3 months.
Options Flow
Normal options activity with a slight bearish tilt as implied volatility remains high, reflecting uncertainty.
Earnings Intelligence
Next Earnings
Estimated early May 2026
Surprise Probability
Low
Historical Earnings Pattern
Historically, the stock tends to be highly volatile around earnings, often reacting negatively to updates that do not provide clear clinical differentiation or extend the cash runway significantly.
Key Metrics to Watch
Competitive Position
Top Competitor
CRISPR Therapeutics (CRSP)
Market Share Trend
Losing ground. Competitors like CRISPR Therapeutics have approved therapies (Casgevy), setting a very high bar for Editas to differentiate and gain future market share.
Valuation vs Peers
EDIT currently trades at a significant discount on forward P/S and P/B multiples compared to more advanced CRISPR peers (CRSP, NTLA) due to its earlier stage pipeline and financial distress.
Competitive Advantages
- •Foundational CRISPR/Cas9 intellectual property portfolio
- •EDIT-301 targeting severe Sickle Cell Disease and Beta Thalassemia with potentially superior engraftment
- •Experienced scientific team in gene editing
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive EDIT Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early May 2026)
- •Further updates on EDIT-301 Phase 1/2 clinical trial patient enrollment and dosing
Medium-Term (6-18 months)
- •Potential early data readout or expanded cohort results for EDIT-301 (late 2026 / early 2027)
- •Strategic partnership or licensing agreement announcement for pipeline assets
Long-Term (18+ months)
- •Positive Phase 2/3 data for EDIT-301 leading to regulatory pathway discussions
- •Advancement of earlier-stage pipeline candidates beyond preclinical stages
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for EDIT?
- ✓
Positive and differentiated clinical trial data for EDIT-301 (e.g., durable engraftment, reduced transfusions)
- ✓
Announcement of a strategic partnership or non-dilutive financing that significantly extends cash runway
- ✓
Evidence of effective cost control and reduction in cash burn
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Editas Medicine Inc (EDIT)?
As of March 25, 2026, Editas Medicine Inc has a DVR Score of 2.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the risk level for EDIT stock?
Our analysis rates Editas Medicine Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the EDIT DVR analysis updated?
Our AI-powered analysis of Editas Medicine Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 25, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for EDIT (Editas Medicine Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.